{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:47:13Z","timestamp":1790794033756,"version":"4.1.0"},"reference-count":125,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease, the most common form of dementia, is characterized by the deposition of amyloid plaques and neurofibrillary tangles in the brain, leading to the loss of neurons and a decline in a person\u2019s memory and cognitive function. As a multifactorial disease, Alzheimer\u2019s involves multiple pathogenic mechanisms, making its treatment particularly challenging. Current drugs approved for the treatment of Alzheimer\u2019s disease only alleviate symptoms but cannot stop the progression. Moreover, these drugs typically target a single pathogenic mechanism, leaving other contributing factors unaddressed. Recent advancements in drug design have led to the development of multi-target-directed ligands (MTDLs), which have gained popularity for their ability to simultaneously target multiple pathogenic mechanisms. This paper focuses on analyzing the activity, mechanism of action, and binding properties of the anti-Alzheimer\u2019s MTDLs developed between 2020 and 2024.<\/jats:p>","DOI":"10.3390\/ijms26010157","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T09:13:32Z","timestamp":1735290812000},"page":"157","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Recent Advances in the Search for Effective Anti-Alzheimer\u2019s Drugs"],"prefix":"10.3390","volume":"26","author":[{"given":"Martyna","family":"Ogos","sequence":"first","affiliation":[{"name":"Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna Str. 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Stary","sequence":"additional","affiliation":[{"name":"Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna Str. 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-0354","authenticated-orcid":false,"given":"Marek","family":"Bajda","sequence":"additional","affiliation":[{"name":"Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna Str. 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"ref_1","unstructured":"World Health Organisation (2023, December 30). Dementia. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref_2","unstructured":"Sheppard, O., and Coleman, M. (2020). Alzheimer\u2019s Disease: Etiology, Neuropathology and Pathogenesis. Alzheimer\u2019s Disease: Drug Discovery, Exon Publications."},{"key":"ref_3","first-page":"832","article-title":"From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer\u2019s Disease","volume":"19","author":"Mallea","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_4","first-page":"285","article-title":"Review of drugs for Alzheimer\u2019s disease","volume":"6","author":"Sun","year":"2012","journal-title":"Drug Discov. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chen, Z.-R., Huang, J.-B., Yang, S.-L., and Hong, F.-F. (2022). Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules, 27.","DOI":"10.3390\/molecules27061816"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113154","DOI":"10.1016\/j.ejmech.2021.113154","article-title":"Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"213","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1515\/revneuro-2019-0089","article-title":"Amyloid-\u03b2, tau, and the cholinergic system in Alzheimer\u2019s disease: Seeking direction in a tangle of clues","volume":"31","author":"Majdi","year":"2020","journal-title":"Rev. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie-Cioara, F.L., Toma, M.M., Bungau, S., and Bumbu, A.G. (2021). Role of Monoamine Oxidase Activity in Alzheimer\u2019s Disease: An Insight into the Therapeutic Potential of Inhibitors. Molecules, 26.","DOI":"10.3390\/molecules26123724"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, J., Chang, L., Song, Y., Li, H., and Wu, Y. (2019). The Role of NMDA Receptors in Alzheimer\u2019s Disease. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00043"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1039\/c0mt00074d","article-title":"Role of metal dyshomeostasis in Alzheimer\u2019s disease","volume":"3","author":"Bonda","year":"2011","journal-title":"Metallomics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-020-00189-z","article-title":"Current understanding of metal ions in the pathogenesis of Alzheimer\u2019s disease","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","article-title":"The \u03b2-Secretase Enzyme BACE in Health and Alzheimer\u2019s Disease: Regulation, Cell Biology, Function, and Therapeutic Potential","volume":"29","author":"Vassar","year":"2009","journal-title":"J. Neuroscience"},{"key":"ref_15","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer\u2019s therapeutics","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","article-title":"Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease:: Getting on and staying on","volume":"64","author":"Grossberg","year":"2003","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1016\/j.bmc.2014.07.009","article-title":"Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer\u2019s disease therapy","volume":"22","author":"Li","year":"2014","journal-title":"Bioorganic Med. Chem."},{"key":"ref_18","unstructured":"(2023, December 30). How Is Alzheimer\u2019s Disease Treated? National Institute on Aging, Available online: https:\/\/www.nia.nih.gov\/health\/alzheimers-treatment\/how-alzheimers-disease-treated."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","article-title":"The chemical biology of clinically tolerated NMDA receptor antagonists","volume":"97","author":"Chen","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e01831","DOI":"10.1002\/brb3.1831","article-title":"Memantine, Donepezil, or Combination Therapy\u2014What is the best therapy for Alzheimer\u2019s Disease? A Network Meta-Analysis","volume":"10","author":"Guo","year":"2020","journal-title":"Brain Behav."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"114354","DOI":"10.1016\/j.ejmech.2022.114354","article-title":"Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer\u2019s disease","volume":"236","author":"Turcu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1756285611404470","article-title":"Disease-modifying treatments for Alzheimer\u2019s disease","volume":"4","author":"Galimberti","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Chi, Y., Zhang, Q., and Ma, Y. (2023). Safety and efficacy of lecanemab for Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized clinical trials. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1169499"},{"key":"ref_24","first-page":"9343514","article-title":"Aducanumab Therapy to Treat Alzheimer\u2019s Disease: A Narrative Review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int. J. Alzheimers Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","article-title":"A Perspective on Multi-target Drugs for Alzheimer\u2019s Disease","volume":"41","author":"Benek","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.lfs.2018.06.025","article-title":"Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer\u2019s disease","volume":"207","author":"Wenzel","year":"2018","journal-title":"Life Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed Multiple Ligands. An Emerging Drug Discovery Paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by Design: A Medicinal Chemist\u2019s Perspective on Multitargeting Compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12230","DOI":"10.1038\/s41598-017-12061-8","article-title":"Network Analysis of Drug\u2013target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a Single Drug: Multitarget Drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zag\u00f3rska, A., and Jaromin, A. (2020). Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer\u2032s Disease Therapy. Molecules, 25.","DOI":"10.3390\/molecules25153337"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hung, S.-Y., and Fu, W.-M. (2017). Drug candidates in clinical trials for Alzheimer\u2019s disease. J. Biomed. Sci., 24.","DOI":"10.1186\/s12929-017-0355-7"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114045","DOI":"10.1016\/j.ejmech.2021.114045","article-title":"The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer\u2019s disease with comorbid depression","volume":"229","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113224","DOI":"10.1016\/j.ejmech.2021.113224","article-title":"Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer\u2019s action: Design, synthesis, crystal structure and in-vitro biological evaluation","volume":"215","author":"Manzoor","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114358","DOI":"10.1016\/j.ejmech.2022.114358","article-title":"Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer\u2019s disease","volume":"237","author":"Brunetti","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"114806","DOI":"10.1016\/j.ejmech.2022.114806","article-title":"Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer\u2019s disease","volume":"244","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"114841","DOI":"10.1016\/j.ejmech.2022.114841","article-title":"Discovery of novel hybrids containing clioquinol\u22121-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer\u2019s disease","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"111916","DOI":"10.1016\/j.ejmech.2019.111916","article-title":"1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer\u2019s disease","volume":"187","author":"Wichur","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"114098","DOI":"10.1016\/j.ejmech.2021.114098","article-title":"Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer\u2019s disease","volume":"230","author":"Shi","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"112180","DOI":"10.1016\/j.ejmech.2020.112180","article-title":"The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer\u2019s disease","volume":"192","author":"Sang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"113792","DOI":"10.1016\/j.ejmech.2021.113792","article-title":"Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT6R antagonists with \u03b2-amyloid anti-aggregation properties","volume":"225","author":"Wichur","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1039\/C9MD00441F","article-title":"Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer\u2019s disease","volume":"11","author":"Wang","year":"2020","journal-title":"RSC Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Qin, P., Ran, Y., Xie, F., Liu, Y., Wei, C., Luan, X., and Wu, J. (2023). Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC\/AChE inhibitors for Alzheimer\u2019s disease. Bioorganic Med. Chem., 80.","DOI":"10.1016\/j.bmc.2023.117178"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Malek, R., Simakov, A., Davis, A., Maj, M., Bernard, P.J., Wnorowski, A., Martin, H., Marco-Contelles, J., Chabchoub, F., and Dallemagne, P. (2022). Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules, 28.","DOI":"10.3390\/molecules28010071"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Queda, F., Cal\u00f2, S., Gwizdala, K., Magalh\u00e3es, J.D., Cardoso, S.M., Chaves, S., Piemontese, L., and Santos, M.A. (2021). Novel Donepezil\u2013Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer\u2019s Disease. Molecules, 26.","DOI":"10.3390\/molecules26061658"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Tamaddon-Abibigloo, Y., Dastmalchi, S., Razzaghi-Asl, N., and Mojarrad, J.S. (2024). Design, synthesis, in vitro and in silico evaluations of new isatin-triazine- aniline hybrids as potent anti- Alzheimer multi-target directed lead compounds. Bioorganic Chem., 147.","DOI":"10.1016\/j.bioorg.2024.107355"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","article-title":"Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer\u2019s Disease","volume":"64","author":"Rossi","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"112751","DOI":"10.1016\/j.ejmech.2020.112751","article-title":"Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer\u2019s disease","volume":"207","author":"Jiang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"114152","DOI":"10.1016\/j.ejmech.2022.114152","article-title":"Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer\u2019s agents","volume":"231","author":"Waly","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1080\/14756366.2022.2122054","article-title":"Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities","volume":"37","author":"Chrienova","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1021\/acschemneuro.1c00184","article-title":"Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer\u2019s Disease","volume":"12","author":"Gorecki","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"26012","DOI":"10.1021\/acsomega.3c02051","article-title":"Modified Tacrine Derivatives as Multitarget-Directed Ligands for the Treatment of Alzheimer\u2019s Disease: Synthesis, Biological Evaluation, and Molecular Modeling Study","volume":"8","author":"Fares","year":"2023","journal-title":"ACS Omega"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Long, J., Qin, F., Luo, J., Zhong, G., Huang, S., Jing, L., Yi, T., Liu, J., and Jiang, N. (2024). Design, synthesis, and biological evaluation of novel capsaicin-tacrine hybrids as multi-target agents for the treatment of Alzheimer\u2019s disease. Bioorganic Chem., 143.","DOI":"10.1016\/j.bioorg.2023.107026"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"114044","DOI":"10.1016\/j.ejmech.2021.114044","article-title":"Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer\u2019s disease","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"112265","DOI":"10.1016\/j.ejmech.2020.112265","article-title":"Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer\u2019s disease","volume":"194","author":"Sang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Xia, J., Dong, S., Yang, L., Wang, F., Xing, S., Du, J., and Li, Z. (2024). Design, synthesis, and biological evaluation of novel tryptanthrin derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. Bioorganic Chem., 143.","DOI":"10.1016\/j.bioorg.2023.106980"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dakhlaoui, I., Bernard, P.J., Pietrzak, D., Simakov, A., Maj, M., Refouvelet, B., B\u00e9duneau, A., Cornu, R., Jozwiak, K., and Chabchoub, F. (2023). Exploring the Potential of Sulfonamide-Dihydropyridine Hybrids as Multitargeted Ligands for Alzheimer\u2019s Disease Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119742"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"115145","DOI":"10.1016\/j.ejmech.2023.115145","article-title":"Discovery of multi-target directed 3-OH pyrrolidine derivatives through a semisynthetic approach from alkaloid vasicine for the treatment of Alzheimer\u2019s disease","volume":"249","author":"Bhanukiran","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115288","DOI":"10.1016\/j.ejmech.2023.115288","article-title":"Synthesis and anti-Alzheimer potential of novel \u03b1-amino phosphonate derivatives and probing their molecular interaction mechanism with acetylcholinesterase","volume":"253","author":"Rao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113397","DOI":"10.1016\/j.ejmech.2021.113397","article-title":"Discovery of multifunctional anti-Alzheimer\u2019s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and \u03b3-aminobutyric acid transporters","volume":"218","author":"Pasieka","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"112743","DOI":"10.1016\/j.ejmech.2020.112743","article-title":"Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer\u2019s disease","volume":"207","author":"Bajda","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gody\u0144, J., Zar\u0119ba, P., Stary, D., Kaleta, M., Kuder, K.J., Latacz, G., Mogilski, S., Reiner-Link, D., Frank, A., and Doroz-P\u0142onka, A. (2022). Benzophenone Derivatives with Histamine H3 Receptor Affinity and Cholinesterase Inhibitory Potency as Multitarget-Directed Ligands for Possible Therapy of Alzheimer\u2019s Disease. Molecules, 28.","DOI":"10.3390\/molecules28010238"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2175821","DOI":"10.1080\/14756366.2023.2175821","article-title":"Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer\u2019s disease","volume":"38","author":"Hafez","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Hu, C., Jiang, L., Tang, L., Zhang, M., and Sheng, R. (2021). Design, synthesis and biological evaluation of 2-styryl-5-hydroxy-4-pyrone derivatives and analogues as multiple functional agents with the potential for the treatment of Alzheimer\u2019s disease. Bioorganic Med. Chem., 44.","DOI":"10.1016\/j.bmc.2021.116306"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"115169","DOI":"10.1016\/j.ejmech.2023.115169","article-title":"Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer\u2019s disease","volume":"250","author":"Tonelli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Malafaia, D., Oliveira, A., Fernandes, P.A., Ramos, M.J., Albuquerque, H.M.T., and Silva, A.M.S. (2021). Chromeno[3,4-b]xanthones as First-in-Class AChE and A\u03b2 Aggregation Dual-Inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084145"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/acschemneuro.0c00624","article-title":"Multitarget Biological Profiling of New Naphthoquinone and Anthraquinone-Based Derivatives for the Treatment of Alzheimer\u2019s Disease","volume":"12","author":"Campora","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/acschemneuro.2c00357","article-title":"Discovery of Dual A\u03b2\/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer\u2019s Disease","volume":"13","author":"Gandini","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1021\/acschemneuro.3c00464","article-title":"Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on \u03b1-Synuclein and Tau Aggregation","volume":"14","author":"Ramirez","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2300404","DOI":"10.1002\/ardp.202300404","article-title":"Discovery of novel harmine derivatives as GSK-3\u03b2\/DYRK1A dual inhibitors for Alzheimer\u2019s disease treatment","volume":"357","author":"Qiu","year":"2024","journal-title":"Arch. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"113819","DOI":"10.1016\/j.ejmech.2021.113819","article-title":"Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer\u2019s agents by the combination of pharmacophore-based and structure-based design","volume":"226","author":"Hoang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"112475","DOI":"10.1016\/j.ejmech.2020.112475","article-title":"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-\u03b2 aggregation against Alzheimer\u2019s disease","volume":"202","author":"Xie","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Jiang, X., Guo, J., Lv, Y., Yao, C., Zhang, C., Mi, Z., Shi, Y., Gu, J., Zhou, T., and Bai, R. (2020). Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity. Bioorganic Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115550"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Vicente-Zurdo, D., Brunetti, L., Piemontese, L., Guedes, B., Cardoso, S.M., Chavarria, D., Borges, F., Madrid, Y., Chaves, S., and Santos, M.A. (2023). Rivastigmine\u2013Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098312"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113112","DOI":"10.1016\/j.ejmech.2020.113112","article-title":"2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer\u2019s disease","volume":"211","author":"Mezeiova","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"113426","DOI":"10.1016\/j.ejmech.2021.113426","article-title":"Design, synthesis, and biological evaluation of diosgenin-indole derivatives as dual-functional agents for the treatment of Alzheimer\u2019s disease","volume":"219","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1039\/D3MD00308F","article-title":"Novel styryl-thiazole hybrids as potential anti-Alzheimer\u2019s agents","volume":"14","author":"Gouleni","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1021\/acschemneuro.3c00269","article-title":"Discovery of Multitarget-Directed Ligands from Piperidine Alkaloid Piperine as a Cap Group for the Management of Alzheimer\u2019s Disease","volume":"14","author":"Bhanukiran","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"116409","DOI":"10.1016\/j.ejmech.2024.116409","article-title":"Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer\u2019s disease therapy","volume":"271","author":"Waiker","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Schwarthoff, S., Tischer, N., Sager, H., Sch\u00e4tz, B., Rohrbach, M.M., Raztsou, I., Robaa, D., Gaube, F., Arndt, H.-D., and Winckler, T. (2021). Evaluation of \u03b3-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors. Bioorganic Med. Chem., 46.","DOI":"10.1016\/j.bmc.2021.116355"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Bachurin, S.O., Shevtsova, E.F., Makhaeva, G.F., Aksinenko, A.Y., Grigoriev, V.V., Goreva, T.V., Epishina, T.A., Kovaleva, N.V., Boltneva, N.P., and Lushchekina, S.V. (2022). Conjugates of Methylene Blue with Cycloalkaneindoles as New Multifunctional Agents for Potential Treatment of Neurodegenerative Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213925"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.ejmech.2011.04.038","article-title":"Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine derivatives as acetylcholinesterase inhibitors","volume":"46","author":"Szymanski","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Aso, E., and Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer\u2019s disease: Moving toward the clinic. Front. Pharmacol., 5.","DOI":"10.3389\/fphar.2014.00037"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41419-018-0688-5","article-title":"The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer\u2019s disease model","volume":"9","author":"Fan","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/alzrt241","article-title":"Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition","volume":"6","author":"Selenica","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Orozco, D.R., and Garlapati, S. (2020). Histone deacetylase inhibitors induce expression of chromosomally tagged variant-specific surface protein genes in Giardia lamblia. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-04995-6"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acschemneuro.8b00530","article-title":"Design, Synthesis, and Evaluation of Novel Ferulic Acid Derivatives as Multi-Target-Directed Ligands for the Treatment of Alzheimer\u2019s Disease","volume":"10","author":"Sang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_89","unstructured":"(2024, April 10). Pitolisant, Drugbank. Available online: https:\/\/go.drugbank.com\/drugs\/DB11642."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1016\/j.bmc.2018.08.011","article-title":"Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer\u2019s disease","volume":"26","author":"Cheng","year":"2018","journal-title":"Bioorganic Med. Chem."},{"key":"ref_91","unstructured":"(2024, April 10). MK-0249, MedChemExpress. Available online: https:\/\/www.medchemexpress.com\/MK-0249.html."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1021\/acs.jpcb.6b07045","article-title":"Primary Fibril Nucleation of Aggregation Prone Tau Fragments PHF6 and PHF6","volume":"121","author":"Smit","year":"2017","journal-title":"J. Phys. Chem. B"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"113554","DOI":"10.1016\/j.ejmech.2021.113554","article-title":"Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3\u03b2\/DYRK1A dual inhibitors for the treatment of Alzheimer\u2019s disease","volume":"222","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1021\/acs.jmedchem.7b00098","article-title":"Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer\u2019s Agents Based on Rational Design","volume":"60","author":"Hoang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.9b00751","article-title":"Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer\u2019s Agents by Structure-Based Design","volume":"62","author":"Hoang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid-\u03b2 Load and Cognitive Decline in Alzheimer\u2019s Disease","volume":"39","author":"Morawski","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/nm.1872","article-title":"Glutaminyl cyclase inhibition attenuates pyroglutamate A\u03b2 and Alzheimer\u2019s disease\u2013like pathology","volume":"14","author":"Schilling","year":"2008","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/jnc.15114","article-title":"Increased glutaminyl cyclase activity in brains of Alzheimer\u2019s disease individuals","volume":"156","author":"Gunn","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8590578","article-title":"The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Huntington\u2019s Disease: A Mini Review","volume":"2016","author":"Manoharan","year":"2016","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of Glutamate and NMDA Receptors in Alzheimer\u2019s Disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Makhaeva, G.F., Lushchekina, S.V., Boltneva, N.P., Sokolov, V.B., Grigoriev, V.V., Serebryakova, O.G., Vikhareva, E.A., Aksinenko, A.Y., Barreto, G.E., and Aliev, G. (2015). Conjugates of \u03b3-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. Sci. Rep., 5.","DOI":"10.1038\/srep13164"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Zeng, Y., Zheng, Y., Zhang, T., Ye, F., Zhan, L., Kou, Z., Zhu, S., and Gao, Z. (2022). Identification of a Subtype-Selective Allosteric Inhibitor of GluN1\/GluN3 NMDA Receptors. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.888308"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Huang, L.-K., Kuan, Y.-C., Lin, H.-W., and Hu, C.-J. (2023). Clinical trials of new drugs for Alzheimer disease: A 2020\u20132023 update. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00976-6"},{"key":"ref_105","unstructured":"(2024, December 13). Remternetug. Available online: https:\/\/www.alzforum.org\/therapeutics\/remternetug."},{"key":"ref_106","unstructured":"(2024, December 13). Solanezumab. Available online: https:\/\/www.alzforum.org\/therapeutics\/solanezumab."},{"key":"ref_107","unstructured":"(2024, December 13). ALZ-801. Available online: https:\/\/www.alzforum.org\/therapeutics\/alz-801."},{"key":"ref_108","unstructured":"(2024, December 13). Simufilam. Available online: https:\/\/www.alzforum.org\/therapeutics\/simufilam."},{"key":"ref_109","unstructured":"(2024, December 13). Varoglutamstat. Available online: https:\/\/www.alzforum.org\/therapeutics\/varoglutamstat."},{"key":"ref_110","unstructured":"(2024, December 13). ABBV-916. Available online: https:\/\/www.alzforum.org\/therapeutics\/abbv-916."},{"key":"ref_111","unstructured":"(2024, December 13). CT1812. Available online: https:\/\/www.alzforum.org\/therapeutics\/ct1812."},{"key":"ref_112","unstructured":"(2024, December 13). UCB Presents Encouraging Data on Bepranemab in Early Alzheimer\u2019s Disease in Phase 2a Study at CTAD 2024. Available online: https:\/\/www.drugs.com\/clinical_trials\/ucb-presents-encouraging-data-bepranemab-early-alzheimer-s-phase-2a-study-ctad-2024-21735.html."},{"key":"ref_113","unstructured":"(2024, December 13). Posdinemab. Available online: https:\/\/www.alzforum.org\/therapeutics\/posdinemab."},{"key":"ref_114","unstructured":"(2024, December 13). ACI-35. Available online: https:\/\/www.alzforum.org\/therapeutics\/aci-35."},{"key":"ref_115","unstructured":"(2024, December 13). E2814. Available online: https:\/\/www.alzforum.org\/therapeutics\/e2814."},{"key":"ref_116","unstructured":"(2024, December 13). Ceperognastat. Available online: https:\/\/www.alzforum.org\/therapeutics\/ceperognastat."},{"key":"ref_117","unstructured":"(2024, December 13). BIIB080. Available online: https:\/\/www.alzforum.org\/therapeutics\/biib080."},{"key":"ref_118","unstructured":"(2024, December 13). Fosgonimeton. Available online: https:\/\/www.alzforum.org\/therapeutics\/fosgonimeton."},{"key":"ref_119","unstructured":"(2024, December 13). AR1001. Available online: https:\/\/www.alzforum.org\/therapeutics\/ar1001."},{"key":"ref_120","unstructured":"(2024, December 14). Buntanetap. Available online: https:\/\/www.alzforum.org\/therapeutics\/buntanetap."},{"key":"ref_121","unstructured":"(2024, December 14). KarXT. Available online: https:\/\/www.alzforum.org\/therapeutics\/karxt."},{"key":"ref_122","unstructured":"(2024, December 14). Nilotinib. Available online: https:\/\/www.alzforum.org\/therapeutics\/nilotinib."},{"key":"ref_123","unstructured":"(2024, December 14). Piromelatine. Available online: https:\/\/www.alzforum.org\/therapeutics\/piromelatine."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer\u2019s disease: Results from a randomized, placebo-controlled, phase 3, clinical trial","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"ref_125","unstructured":"(2024, December 14). Bezisterim. Available online: https:\/\/www.alzforum.org\/therapeutics\/bezisterim."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/1\/157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:01:29Z","timestamp":1760115689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/1\/157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26010157"],"URL":"https:\/\/doi.org\/10.3390\/ijms26010157","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}